Guardant Health Inc. Stock News

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2021 after marke

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has initiated the Observation of ResiduAl Cancer with Liquid biopsy Evaluation (ORACLE)

Guardant Health Inc (NASDAQ: GH) has decided not to pursue a potential acquisition of NeoGenomics Inc (NASDAQ: NEO), Bloomberg reported citing people familiar with the matter. Related:   Guardan

The stock price of Guardant Health Inc (NASDAQ: GH) fell by 14% in the previous trading session. This is why it happened.

Investors aren't fans of an acquisition the diagnostics company is rumored to be considering.

Bloomberg reported that Guardant Health Inc (NASDAQ: GH) is reportedly exploring an acquisition of NeoGenomics Inc (NASDAQ: NEO), citing people familiar with the matter.  Related:   Precision O

Both of these companies boast exciting growth prospects.

The pandemic isn't over yet.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, share data highlighting molecular targets of importanc

REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) along with leading academic institutions and pharmaceutical companies will present data demonstrating the ad

REDWOOD CITY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating virtually in the up

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming UBS Genomics 2.0 and

After the market close on Thursday, Guardant Health Inc (NASDAQ: GH) reported Q2 revenues increased 39% Y/Y to $92.1 million, beating the consensus of $84.61 million. Guardant's oncology testing re

Guardant Health's (GH) CEO Helmy Eltoukhy on Q2 2021 Results - Earnings Call Transcript

There's both rhyme and reason for checking out these four stocks.